



Toxicological Profile for Antimony and Compounds

October 2019



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
October 2019	Final toxicological profile released
April 2017	Draft for public comment toxicological profile released
September 1992	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Melanie Buser, M.P.H. (Lead)
Susan Zells Ingber, A.B., M.S.P.P.

Lisa Ingerman, Ph.D., D.A.B.T.
H. Danielle Johnson, B.S.
Mary Kawa, M.A.
Mario Citra, Ph.D.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. David Dorman, DVM, Ph.D., DABVT, DABT, Professor, Toxicology, School of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina
2. Nelson Belzile, Ph.D., Full Professor, Chair, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, Canada
3. Jeffrey L Burgess, MD, MPH, MS, Professor, Associate Dean for Research, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

FOREWORD	ii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs)	5
CHAPTER 2. HEALTH EFFECTS.....	11
2.1 INTRODUCTION.....	11
2.2 DEATH	55
2.3 BODY WEIGHT.....	56
2.4 RESPIRATORY.....	57
2.5 CARDIOVASCULAR.....	60
2.6 GASTROINTESTINAL.....	62
2.7 HEMATOLOGICAL	63
2.8 MUSCULOSKELETAL	65
2.9 HEPATIC.....	65
2.10 RENAL	66
2.11 DERMAL.....	67
2.12 OCULAR	67
2.13 ENDOCRINE.....	68
2.14 IMMUNOLOGICAL	69
2.15 NEUROLOGICAL.....	70
2.16 REPRODUCTIVE	71
2.17 DEVELOPMENTAL.....	71
2.18 OTHER NONCANCER.....	73
2.19 CANCER.....	74
2.20 GENOTOXICITY	75
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	81
3.1 TOXICOKINETICS	81
3.1.1 Absorption.....	81
3.1.2 Distribution	83
3.1.3 Metabolism.....	87
3.1.4 Excretion	87
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	89
3.1.6 Animal-to-Human Extrapolations	89
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	90
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	91
3.3.1 Biomarkers of Exposure.....	92
3.3.2 Biomarkers of Effect.....	92

3.4	INTERACTIONS WITH OTHER CHEMICALS	92
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		93
4.1	CHEMICAL IDENTITY	93
4.2	PHYSICAL AND CHEMICAL PROPERTIES	95
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		99
5.1	OVERVIEW	99
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	100
5.2.1	Production	100
5.2.2	Import/Export.....	104
5.2.3	Use	105
5.2.4	Disposal.....	106
5.3	RELEASES TO THE ENVIRONMENT	106
5.3.1	Air	107
5.3.2	Water.....	113
5.3.3	Soil	113
5.4	ENVIRONMENTAL FATE	114
5.4.1	Transport and Partitioning.....	114
5.4.2	Transformation and Degradation	117
5.5	LEVELS IN THE ENVIRONMENT.....	119
5.5.1	Air	121
5.5.2	Water.....	130
5.5.3	Sediment and Soil	133
5.5.4	Other Media	135
5.6	GENERAL POPULATION EXPOSURE.....	135
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	146
CHAPTER 6. ADEQUACY OF THE DATABASE.....		148
6.1	INFORMATION ON HEALTH EFFECTS.....	148
6.2	IDENTIFICATION OF DATA NEEDS	150
6.3	ONGOING STUDIES.....	157
CHAPTER 7. REGULATIONS AND GUIDELINES		158
CHAPTER 8. REFERENCES		161
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR ANTIMONY	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR ANTIMONY	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F.	GLOSSARY	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Antimony.....	3
1-2. Health Effects Found in Animals Following Oral Exposure to Antimony.....	4
1-3. Summary of Sensitive Targets of Antimony – Inhalation	8
1-4. Summary of Sensitive Targets of Antimony – Oral	9
2-1. Overview of the Number of Studies Examining Antimony Health Effects.....	15
2-2. Levels of Significant Exposure to Antimony – Inhalation	36
2-3. Levels of Significant Exposure to Antimony – Oral	48
5-1. Number of NPL Sites with Antimony or Antimony Compounds Contamination.....	99
6-1. Summary of Existing Health Effects Studies on Antimony By Route and Endpoint.....	149

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Antimony	10
2-1. Health Effects in Humans Exposed to Antimony Dusts	16
2-2. Health Effects in Humans Orally Exposed to Antimony	21
2-3. Levels of Significant Exposure to Antimony – Inhalation	26
2-4. Levels of Significant Exposure to Antimony – Oral	41
2-5. Levels of Significant Exposure to Antimony – Dermal	52
2-6. Genotoxicity of Antimony <i>In Vivo</i>	76
2-7. Genotoxicity of Antimony <i>In Vitro</i>	78
3-1. Background Levels of Antimony Found in Various Tissues of Humans	84
4-1. Chemical Identity of Antimony and Compounds	93
4-2. Physical and Chemical Properties of Antimony and Compounds	96
5-1. Facilities that Produce, Process, or Use Antimony	100
5-2. Facilities that Produce, Process, or Use Antimony Compounds	102
5-3. Releases to the Environment from Facilities that Produce, Process, or Use Antimony	107
5-4. Releases to the Environment from Facilities that Produce, Process, or Use Antimony Compounds	108
5-5. 2011 National Emission Inventory (NEI) Total National Emissions	111
5-6. Lowest Limit of Detection Based on Standards	120
5-7. Summary of Environmental Levels of Antimony	120
5-8. Antimony Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	121
5-9. Median Antimony Levels in Ambient Air	121
5-10. Total Antimony Levels in Water Samples Collected at Yellowstone National Park	131
5-11. Antimony Levels at Three Locations With Different Vehicular Traffic	133
5-12. Geometric Mean and Selected Percentiles of Urinary Antimony (in $\mu\text{g/L}$) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)	137

5-13. Geometric Mean and Selected Percentiles of Urinary Antimony (Creatinine Corrected) (in $\mu\text{g/g}$ of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES).....	141
7-1. Regulations and Guidelines Applicable to Antimony	158